Rituximab Transplant denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab transplant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Rituximab (Transplant) as Non-Formulary

A non-formulary denial means BCBS's pharmacy or medical benefit formulary does not list rituximab for the transplant-related indication being requested, or lists it only under a restricted tier requiring special authorization. This often happens because rituximab's transplant uses — such as desensitization or rejection treatment — may be classified differently than its oncology or rheumatology uses, and the formulary exception process is not automatically triggered by the initial request.

Importantly, a non-formulary denial is not a clinical determination that rituximab is wrong for the patient — it is an administrative classification that can be overridden through a formulary exception or appeal.

## Your Appeal Rights

Under ACA Section 2719, plans subject to ACA rules must allow internal appeal and external review of adverse benefit determinations, including formulary denials. ERISA Section 503 provides equivalent protections for employer-sponsored plans. File your internal appeal within 180 days of the denial notice. If the internal appeal is denied, request independent external review within four months of the final denial. Expedited review is available when waiting would seriously jeopardize health.

## Building a Strong Non-Formulary Appeal

A formulary exception appeal succeeds when you demonstrate that no formulary alternative is clinically appropriate — or that there is no meaningful formulary alternative for this specific transplant indication.

Documentation to assemble: - Prescriber letter specifically requesting a formulary exception, explaining why rituximab is medically necessary and why listed formulary alternatives (if any exist) cannot be substituted - Documentation that any formulary alternatives were considered and are clinically inappropriate, contraindicated for this patient, or simply do not have an approved or recognized role in this transplant context (your transplant physician should state this) - Transplant program records establishing the treating center's protocol and clinical rationale - Relevant guidance from recognized transplant medicine societies, cited generically by organization name

## Formulary Exception Criteria-Mapping

Request BCBS's formulary exception policy in writing. Most plans use a standard framework: - Step 1: Identify the formulary alternative BCBS claims exists for this indication - Step 2: For each alternative listed, obtain a statement from the prescriber explaining why it is not appropriate for this patient - Step 3: Map each exception criterion to chart evidence, using the format: Policy requires [X] — Patient record shows [Y per chart note dated Z]

If BCBS cannot identify a clinically equivalent formulary alternative in the transplant context, the exception must be granted under ACA and ERISA standards.